Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22733786 | 0.81 | TSHR (0.37) | TSHREGFRGAAHTTHSD17B10 | |
| SCHEMBL4760587 | 0.80 | — | — | |
| SCHEMBL11507777 | 0.79 | TSHR (0.35) | TSHREGFRGAAHTTHSD17B10 | |
| SCHEMBL10666482 | 0.77 | — | — | |
| SCHEMBL4761755 | 0.76 | — | — | |
| SCHEMBL5379373 | 0.72 | EPHX2 (0.35) | GAALMNAKMT2A | |
| SCHEMBL1083543 | 0.69 | TSHR (0.42) | TSHREGFRGAAHTTHSD17B10 | |
| SCHEMBL28575878 | 0.68 | PTGS2 (0.34) | ALDH1A1MAPTKMT2A | |
| SCHEMBL5026898 | 0.65 | — | — | |
| SCHEMBL6620859 | 0.65 | TSHR (0.35) | TSHRHTTHSD17B10ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130317013-A1 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | BILLOT XAVIER (CA) | 2013-11-28 | — | — | US | disclosed |
| EP-1513589-B1 | 1,5-DISUBSTITUTED PYRROLID-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TREATMENT OF EYE DISEASES SUCH AS GLAUCOMA | MERCK FROSST CANADA LTD (CA) | 2010-11-10 | — | — | EP | disclosed |
| US-20090258918-A1 | EP4 receptor agonist, compositions and methods thereof | BILLOT XAVIER | 2009-10-15 | — | — | US | disclosed |
| US-20050239872-A1 | 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma | MERCK FROSST CANADA LTD. (CA) | 2005-10-27 | — | — | US | disclosed |
| EP-1513589-A1 | 1,5-DISUBSTITUTED PYRROLID-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TREATMENT OF EYE DISEASES SUCH AS GLAUCOMA | MERCK FROSST CANADA INC. (CA) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003103772-A1 | 1,5-DISTRIBUTED PYRROLID-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TEATMENT OF EYE DISEASES SUCH AS GLAUCOMA | MERCK FROSST CANADA & CO. (CA) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239872-A1 | 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma | PTGER1, PTGER4, PTGER2 | TSHR 402/4885EGFR 1810/4885GAA 4688/4885 |
| US-20090258918-A1 | EP4 receptor agonist, compositions and methods thereof | PTGER4, PTGER1, PTGER3 | TSHR 402/4885EGFR 572/4885GAA 4827/4885 |
| US-20130317013-A1 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | PTGER4, PTGER1, PTGER3 | TSHR 402/4885EGFR 572/4885GAA 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.